Clinical Trials
4 trialsNCT07405164 2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT04924075 2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT03401788 2026-04-13
MK-6482-004
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Active not recruiting
NCT04895748 2026-03-03
DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Phase 1 Terminated